Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The BRCA1-mutated TNBC cell lines MDA-MB-436 and HCC1937 were treated with CBP (10 μM) plus GEM (100 nM) combined with or without olaparib (10 μM) for the indicated times, and then, the cell viability was determined with an MTT assay. The results show data from six independent experiments expressed as the mean ± SD. p < 0.05.

    Sci Rep, 2017, 7:42319. Carboplatin purchased from Selleck.

    Detection of apoptotic responses was found to increase in epimorphin-treated  A1847 with increasing concentrations of carboplatin compared to those of the untreated controls. Data were normalized to the controls and are represented as means ± S.D. [*p<0.05 compared with control]. Images of apoptotic cells were captured at 10X magnification, with at least 3 images per well, using an upright phase-contrast microscope (T3.15A; Fisher Scientific).

    PLoS One 2012 8, e72637. Carboplatin purchased from Selleck.

  • A. MCF10A-Ras overexpressing a vector control or the gene of interest (GeneX), or MCF7 expressing a scramble or a siRNA for the geneX were treated with DMSO or with Carboplatin for 24h. Resistant colonies were allowed to grow for 2 weeks, and are then stained with Crystal Violet. B. Quantification of the results.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Carboplatin for 48h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  NEPSOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomwNk0zPeLCid88US=> NVLQVHE2PzJiaB?= M2TvN4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NIKyU28zPjF|N{GwOS=>
Tca8113/CBP  MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rOW|IuOjYkgJpOwG0> NEnUNpA4OiCq M2X1eYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M1f4SFI3OTN5MUC1
Tca8113/PYM  NUPzflE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzI[5ZwOi1{NfMAje69VQ>? MoezO|IhcA>? MWjpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NVHjPFI4OjZzM{exNFU>
SKOV3 M2K1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfYbphwPjBibXevcYw> MnLlNU02KGR? NUDrdHFscW6qaXLpeJMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?= MYGyOlE{PzB2Mx?=
SKOV3 NXK3R5dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOwMVQh|rypL33s MkTINlQwPDhxN{KgbC=> M2rCOYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? M1O3NlI3OTJ3Mkez
SKOV3 M4rOcGFxd3C2b4Ppd{BCe3OjeR?= MkPwNkDPxGdxbXy= MlzsOFghcA>? NIDxcppqdmS3Y3XzJIFxd3C2b4Ppdy=> NG\udZMzPjF{NUK3Ny=>
OSA M2TKWmNtd26xZ3XubYMhSXO|YYm= M3XFW|IvPS93IN88US=> NVv2[ZI6emW|dXz0d{BqdiCub4fldkBkd2yxbomg[o9zdWG2aX;uJIF{KGOxbYDhdoVlKHSxIHXpeIhmeiCETVmxJJNqWk6DIITy[YF1dWWwdB?= NIToVoMzPjFzME[yNC=>
A549 M4SxO2Z2[3Srb36gRZN{[Xl? M3WyeVAwOjVxNUCg{txO MljjNlQhcA>? M4DjTIRwf26{ZXf1cIF1\XNibXnSMVIxPSCneIDy[ZN{cW:wwrC= MVqyOVkyPzNzNx?=
H1975 M2\sVmZ2[3Srb36gRZN{[Xl? NWG0XGIzOC9{NT:1NEDPxE1? NGK5cpczPCCq M3zGc4Rwf26{ZXf1cIF1\XNibXnSMVIxPSCneIDy[ZN{cW:wwrC= NYe2VJFxOjV7MUezNVc>
A549 MkLjSpVkfGmxbjDBd5NigQ>? Ml;UNE8zPS93MDFOwG0> Mnu2NlQhcA>? NHGwOGR2eHKnZ4XsZZRmeyCvaWKtNlE5KGW6cILld5Nqd25? NVzlV2FYOjV7MUezNVc>
H1975 M2jDNGZ2[3Srb36gRZN{[Xl? MUmwM|I2NzVyIN88US=> NYLTbW1kOjRiaB?= NF\UWHZ2eHKnZ4XsZZRmeyCvaWKtNlE5KGW6cILld5Nqd25? NXvFcIpuOjV7MUezNVc>
A549 NXzYdI02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTGOpY4OjVizszN MX2yOEBp NIHzblRqdmirYnn0d{Bk\WyuIHfyc5d1cA>? M3rDb|I2QTF5M{G3
H1975 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G5cFI2KM7:TR?= NXvYTIlLOjRiaB?= M1nZ[IlvcGmkaYTzJINmdGxiZ4Lve5Rp MoPINlU6OTd|MUe=
MDA-MB-231 NWTSfY8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvr[4QxNTJ{MDFOwIcwdWx? NFXteXg4OiCq NH30TmVKSzVywrC9JFg3KM7:TR?= M{nQWFI2QDN5Nkmx
T47D M{jCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETsSFkxNTJ{MDFOwIcwdWx? M1rU[lczKGh? MXrJR|UxyqB;IES4Mlkh|ryP MmHMNlU5Ozd4OUG=
LCTCC NFjqVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrCbZdKSzVyPUOuPQKBkcL3TR?= NWnoT2R[OjV5N{OxOlc>
MCTCC MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJwOPMAjeK2VQ>? NW\YdmxTOjV5N{OxOlc>
MegTCC M2Tt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;V[pF5UUN3ME20MlHjiIoEtV2= MVqyOVc4OzF4Nx?=
MonoTCC NUDzenpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[yOmlEPTB;NT625qCKyrWP MmfvNlU4PzNzNke=
MCF7 NGe4SWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX4R|lpOjBizszN NVzES4N7PzJiaB?= NETEPY1qdmS3Y3XzJINmdGxiZHXheIghd2ZiSGCx{tIu\GWybHX0[YQhVUOINzDj[Yxtew>? MmL4NlU4PjlyMkW=
A-549  MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;ZNHcxNjVizszN Mkf2NlQhcA>? NGTpd5BFVVORwrC= NGnDV2ZqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 NUO3Ro9mOjV5NUW2PVA>
A-549  NVrjWJRHSXCxcITvd4l{KEG|c3H5 NIXTW28xNjVizszN MlzoOFghcA>? MW\EUXNQyqB? MnK0d4hwf3NiZXHycJkh[XCxcITvd4l{KG[nYYT1doV{KGmwY3z1[Ilv\yCkbHXiZolv\yCjbnSgZ4hzd22jdHnuJINwdmSnboPheIlwdg>? NH7z[FczPTd3NU[5NC=>
A-549  NH\YT4xHfWO2aX;uJGF{e2G7 NUjrUXFpOC53IN88US=> MV60PEBp NVXWe5pPTE2VT9Mg M{e2bpNpd3e|IHHi[ZJz[W62IH3pZ5JwfHWkdXzlJIRqe3K3cITpc44> MmTDNlU4PTV4OUC=
A-549  MVnGeYN1cW:wIFHzd4F6 MoDSNE42KM7:TR?= NFPnVFc1QCCq M4LZSWROW00EoB?= MnfsbY5pcWKrdIOgc4Yh[2WubDDtbYdz[XSrb39CpC=> Mn:xNlU4PTV4OUC=
RMG-1 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJ6LkigxtEhOy54IH3nM2w> M3HyZVI2PzJ4OUGz
FN-RMG-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16zW2lEPTB;NECuOUDDuSB2LkKgcYcwVApizszN NWfQRVVnOjV5Mk[5NVM>
RMG-1-hFUT NFvETG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jsTWlEPTB;NUiuNUDDuSB{LkSgcYcwVA>? M3HPcFI2PzJ4OUGz
FN-RMG-1-hFUT NGnkfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7vTWM2OD1zMUiuPEDDuSBzMz64JI1oN0x? NVnPWZJqOjV5Mk[5NVM>
CHP-134  M3ntfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3ZemkyKM7:TR?= MmnQSG1UV8Li NXqwXHhwcW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz NWnQcYdQOjV4NUi0OlM>
IMR-32 NHjjSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLrcFkyKM7:TR?= MVjEUXNQyqB? MVPpcohq[mm2czDzbYdvcW[rY3HueEBk\WyuIHfyc5d1cCClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> NH6z[IYzPTZ3OES2Ny=>
CHP-134  M4TEemZ2[3Srb36gRZN{[Xl? MkXMNVAh|ryPwrC= MYXEUXNQyqB? NEPXeIFqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? NHnmb24zPTZ3OES2Ny=>
IMR-32 NV7OV2NbTnWldHnvckBCe3OjeR?= NWGwUW12OTBizszNxsA> M4raUmROW00EoB?= M3LLTYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy NX\L[mRwOjV4NUi0OlM>
A549 NHnidWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWwW2ZZOC5{LUSwNFAh|ryP MXG3NkBp MVzJR|UxRTF{NjFCtUA2NjBizszN MlfiNlU3OjV{NEO=
A549/CDDP MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PXR|AvOi12MECwJO69VQ>? M2Hsc|czKGh? NXfSd2ppUUN3ME2yOFDDqMLzwrC0OU44KM7:TR?= MonDNlU3OjV{NEO=
H460  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYWyOEBp NES1PWZFVVOR M2jBZmlEPTB;Nz65JO69VQ>? M4PCSlI2PTl7OUm1
H460  MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vJVVcvQSEQvF2= NVPnc3duOjRiaB?= M1;DdmROW09? M{[0e5Npd3e|IHGgdoFlcW:|ZX7zbZRqgmmwZzDl[oZm[3RidH:gXE1z[Xm| NGrtV3YzPTV7OUm5OS=>
NRK-52E NYftcmtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHUO|LDqGkEoB?= MnfrTWM2OD1zMECgxtEhOTJwOTFOwG0> NYXnUnZNOjV3NkW2NFM>
RGE MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[3NuKhcMLi NUnFU5Z4UUN3ME2yNkDDuSB5LkSg{txO Mn\jNlU2PjV4MEO=
NRK-52E NX64d2h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\ST4pDPzMEoHlCpC=> NH7GdIVKSzhyPUG3PUDDuSB7LkWg{txO Mn\mNlU2PjV4MEO=
RGE NITPSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOxO|LDqGkEoB?= NUHOXYVzUUN6ME22N{DDuSB5LkSg{txO NYHiN3N7OjV3NkW2NFM>
SK-OV-3 M2DLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi1XlJ[PzJiaB?= NXu4bG01UUN3ME2xNFQvQCEQvF2= M{PMRlI2PTJyMUOy
ES-2 NEPa[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;jdVczKGh? MVrJR|UxRTF2Lk[g{txO M3GyUlI2PTJyMUOy
OVCAR-8 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVq3NkBp M2fPNWlEPTB;OU[uNEDPxE1? NXvld3VpOjV3MkCxN|I>
3AO MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGwUnVJPzJiaB?= M{juNGlEPTB;NkOuOEDPxE1? NETQTZkzPTV{MEGzNi=>
A2780 M3;KSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\3O|IhcA>? NWX3PIRjUUN3ME2xOFUvPyEQvF2= MVyyOVUzODF|Mh?=
SW626 NX3yV|ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPUO|IhcA>? M4HFUGlEPTB;OUeuNEDPxE1? NX\BVVJuOjV3MkCxN|I>
OVCAR-3 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\MUVczKGh? NEHTV21KSzVyPUOyMlYh|ryP MWiyOVUzODF|Mh?=
A549 M4D4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF3MT61OkDDuSB3Mz6wOkDPxE1? MmK4NlUzPzd2NkG=
4T1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoniTWM2OD16ND62NkDDuSB|MD6wOUDPxE1MIN88US=> NUPzZ5pVOjV{N{e0OlE>
BALB/3T3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPMTWM2OD1zND6zNEDDuSB4Lk[4JO69VQ>? MoPKNlUzPzd2NkG=
B16 M1r6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLETWM2OD14ND6zNEDDuSB4LkixJO69VQ>? M{\DS|I2Ojd5NE[x
DU 145 NWLlU5FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHUZ3A6UUN3ME2zOU4xPCEEsTCxO{42PCEQvF2= M1KzTVI2Ojd5NE[x
FaDu NU\pfIRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTR3LkO5JOKyKDFzLkWwJO69VQ>? NFfT[nEzPTJ5N{S2NS=>
HCV-29T M3n6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrrSWM6UUN3ME20PE42PyEEsTCyNk41QSEQvF2= M2rWWlI2Ojd5NE[x
HL-60 NIfUTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon1TWM2OD1zMT6xNEDDuSB2LkS3JO69VQ>? NFzYWXozPTJ5N{S2NS=>
HT-29 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrxV|lKSzVyPUi5MlE3KMLzIEG4Mlg3KM7:TR?= NXyweFVZOjV{N{e0OlE>
H146 NGTHcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljrTWM2OD12OT62xtEyOy5zIN88US=> Mk\TNlUyOjR{OEK=
H187 NVm5TlZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rCR2lEPTB;MUKuO:KyOi55IN88US=> NI\2[nYzPTF{NEK4Ni=>
H128 M2K0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPJPFVKSzVyPUGwOk41yrF7Lk[g{txO MUKyOVEzPDJ6Mh?=
H69 NH3veVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTd4LkpCtVI4NjhizszN NX7SeJFSOjVzMkSyPFI>
H209 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJ3OD6xxtE6QS56IN88US=> MomzNlUyOjR{OEK=
DMS153 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2CzOmlEPTB;NUeuPOKyQS5{IN88US=> MWqyOVEzPDJ6Mh?=
H526 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrITWM2OD15LkNCtVEvPyEQvF2= MViyOVEzPDJ6Mh?=
DMS114 M{DHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTh3LklCtVEzNjhizszN NYPmWYdlOjVzMkSyPFI>
DMS53 MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF2Nj6yxtE{Pi52IN88US=> NX;C[oZYOjVzMkSyPFI>
HeLa NHXvO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfJNYJkPS16MDFOwG0> MnP5bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MV:yOVExQTN4MB?=
MCF-7 NWn4U|lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf1OU05OCEQvF2= MU\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NFu2VWkzPTFyOUO2NC=>
MDA-MB-231 M2LWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrPcmh5PS16MDFOwG0> M2nldolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NFPuZ4YzPTFyOUO2NC=>
CaOV3 NYHOWo9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVOw[ZRFPzJiaB?= NYH6V2NFUUN3ME24Ok4yKM7:TR?= MoTiNlUxPjh6NEm=
OVCAR-3 M3TTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT2O|IhcA>? M{T3fGlEPTB;MUe5MlUh|ryP M2nMRlI2ODZ6OES5
OVCAR-5 MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHqPGRUPzJiaB?= MnnBTWM2OD15NT63JO69VQ>? MkPjNlUxPjh6NEm=
SKOV-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfwNWU4OiCq NWK0N4g5UUN3ME21NFQh|ryP M3H5V|I2ODZ6OES5
OVCAR-4 M3fEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TIUVczKGh? MUnJR|UxRTJ7MD62JO69VQ>? MWmyOVA3QDh2OR?=
OVCAR-8 NEnLeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjFbFdPPzJiaB?= Ml71TWM2OD14OUCuNkDPxE1? NXHNcXd6OjVyNki4OFk>
MA148 M3Hqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDoSpIzPCCq M3XCRWlEPTB;OEOuOwKBkcLz4pEJNU41KM7:Zz;tcC=> MVuyOFg{OTB7MR?=
A549 NGG4WpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuyOEBp M{TRVmlEPTB;N{e2MlDjiIoEsfMAjVEvQSEQvHevcYw> M3WwUFI1QDNzMEmx
MDA-MB-231 NHW1VpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLPSngzPCCq Mn3CTWM2OD15NEiuNQKBkcLz4pEJNU4yKM7:Zz;tcC=> NUDETGtsOjR6M{GwPVE>
NCI-ADR/RES  NXf4eVN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDaenJMOjRiaB?= Mk\OTWM2OD1zN{WzMlDjiIoEsfMAjVQvPCEQvHevcYw> M3[yU|I1QDNzMEmx
MA148 NVT2ZoVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\BOFghcA>? MkDQTWM2OD1{OD6x5qCKyrIkgJmxMlAh|rypL33s MoK4NlQ5OzFyOUG=
A549 NWj0Vox1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rEZ|Q5KGh? MWrJR|UxRTFzOD6w5qCKyrIkgJmxMlIh|rypL33s MknhNlQ5OzFyOUG=
MDA-MB-231 MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1K2XVQ5KGh? MofhTWM2OD1zOEOuNQKBkcLz4pEJNU4zKCEQvHevcYw> MoP6NlQ5OzFyOUG=
NCI-ADR/RES  MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq4RZI1QCCq MYrJR|UxRTF7Mz6w5qCKyrIkgJmxMlkh|rypL33s NWTUN5NCOjR6M{GwPVE>
MA148 Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz5O|IhcA>? MWDJR|UxRTF|LkhihKnDueLCiUGuNkDPxGdxbXy= MoTBNlQ5OzFyOUG=
A549 NGDHNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHh[Jo4OiCq M4fqUWlEPTB;NkSuN-KBkcLz4pEJNU4yKM7:Zz;tcC=> M1rkUlI1QDNzMEmx
MDA-MB-231 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vNZlczKGh? MX\JR|UxRTl7LkZihKnDueLCiUGuNUDPxGdxbXy= M4HKd|I1QDNzMEmx
NCI-ADR/RES  MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYS3NkBp NV[1NHozUUN3ME2zO{416oDLwsJihKkyNjdizsznM41t NHnyblEzPDh|MUC5NS=>
A549 NVvhOY5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyy[21yPzJiaB?= NVjPc3BnTE2VTx?= NGrvOnVKSzVyPUG1Nk41ODlizszN NX7DdI5YOjR5MkGzNlM>
NCI-H157 M{m5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvKVFI4OiCq M3\NcWROW09? MYjJR|UxRTh7Lkm3O{DPxE1? NVLmeZROOjR5MkGzNlM>
PC9 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3RO|IhcA>? NFPONnJISzVyPUexMlbDuTlwNTFCuW0> MV6yOFYyQDhyOR?=
A549  NXf5S2ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVW3NkBp NIfRVpdISzVyPUGzOuKyOzFwNjFCuW3DqA>? MXiyOFYyQDhyOR?=
PC9 MnnPRZBweHSxc3nzJGF{e2G7 M3fQ[VExOCEEtV2= NVrSbox{PzJiaB?= NXq2bIZ7cW6mdXPld{BieG:ydH;zbZM> NVvLZlNoOjR4MUi4NFk>
A549  MV;BdI9xfG:|aYOgRZN{[Xl? M4TGUFExOCEEtV2= MmfxO|IhcA>? MXzpcoR2[2W|IHHwc5B1d3Orcx?= M1jqe|I1PjF6OEC5
A549 NHXIRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvYNlQhcA>? NUGweWM5UUNzME2xMlQ4PiCwTR?= NVjPeVhKOjR|OU[0N|c>
H1299 NFnwPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fTNVI1KGh? MVnJR|ExRTBwNESzJI5O NYPBcWYxOjR|OU[0N|c>
HCC15 M2HUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK4NlQhcA>? NETYfZlKSzFyPUCuN|Q3KG6P Mn\YNlQ{QTZ2M{e=
H157 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PPclI1KGh? M1\MNWlEOTB;MD64NUBvVQ>? NXzUWVQ5OjR|OU[0N|c>
A2780 M{i5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M175OWlEPTB;MUSuNQKBkcLz4pEJNU41KM7:TR?= MVSyOFIxQTZ7Mx?=
A2780cisR M3:1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XGbGlEPTB;NEiuPgKBkcLz4pEJN{46KM7:TR?= NVq4PHhzOjR{MEm2PVM>
A2780ZD0473R M3;v[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLETWM2OD14ND625qCKyrIkgJmzMlIh|ryP NVrIO3hHOjR{MEm2PVM>
SKOV-3 NGHjT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLJZ2VKSzVyPUSzMlTjiIoEsfMAjVMvQSEQvF2= NIjhc2QzPDJyOU[5Ny=>

... Click to View More Cell Line Experimental Data

In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
14mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage powder
in solvent
Synonyms JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03694002 Recruiting Locally Advanced Thymic Carcinoma|Metastatic Thymic Carcinoma|Recurrent Thymic Carcinoma|Unresectable Thymic Carcinoma Southwest Oncology Group|National Cancer Institute (NCI) August 9 2018 Phase 2
NCT03513666 Recruiting NSCLC Shanghai Junshi Bioscience Co.Ltd. April 9 2018 Phase 2
NCT03095352 Recruiting Breast Cancer|Chest Wall Disease University of California San Francisco|Mayo Clinic|Johns Hopkins University|Translational Breast Cancer Research Consortium|Massachusetts General Hospital September 9 2017 Phase 2
NCT02775435 Active not recruiting Non-small Cell Lung Cancer Merck Sharp & Dohme Corp. June 9 2016 Phase 3
NCT02151149 Completed Non-Small Cell Lung Cancer|Carcinoma|Squamous Cell Carcinoma|Adenocarcinoma|Carcinoma Large Cell|Lung Neoplasm Celgene June 9 2014 Phase 4
NCT01868022 Completed Neoplasms GlaxoSmithKline October 9 2013 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID